A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Juvenile Idiopathic Arthritis
Спонсор: Eli Lilly and Company
Налично на:
БГ
Обобщение
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Кой може да участва
Inclusion Criteria:
* Participants must have completed a previous study of baricitinib for the treatment of JIA.
Exclusion Criteria:
* Participants must not have had a permanent discontinuation of baricitinib in the prior study.
* Participants must have not developed an allergy to baricitinib.
БГ
EN